Patients with bullous pemphigoid treated with Dupixent maintained disease control and symptom relief, according to phase 2/3 trial results released by Regeneron and Sanofi.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.